Cremolini, C., Rossini, D., Lonardi, S., Antoniotti, C., Pietrantonio, F., Marmorino, F., et al. (2022). Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO. JOURNAL OF CLINICAL ONCOLOGY, 40(17_suppl), 3505-3505 [10.1200/JCO.2022.40.17_suppl.LBA3505].
Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO
Formica V.;Aprile G.;
2022-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
